- Home
- SPEG vs CRBU Comparison
SPEG vs CRBU Comparison
Compare SPEG & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPEG | CRBU |
|---|---|---|
| Founded | 2024 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.7M | 138.3M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPEG | CRBU |
|---|---|---|
| Price | $10.43 | $0.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 26.4K | ★ 4.6M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $145.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $0.44 |
| 52 Week High | $11.03 | $3.53 |
Technical Indicators
Market Signals| Indicator | SPEG | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 63.87 | 24.04 |
| Support Level | $10.26 | $0.44 |
| Resistance Level | $11.03 | $1.72 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 100.00 | 12.99 |
Price Performance
Historical ComparisonAbout SPEG Silver Pegasus Acquisition Corp Class A Ordinary Shares
Silver Pegasus Acquisition Corp is a blank check company.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.